Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously treated (cohorts, A, B \& C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma participants.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Bristol-Myers Squibb
NCT07209059 · Hodgkin Lymphoma, Hodgkin Disease, and more
NCT02287311 · Hodgkin Disease, Non-Hodgkin Lymphoma, and more
NCT07449832 · Hodgkin Disease Lymphoma
NCT04998331 · Hodgkin Disease, Lymphoma, T-Cell, Cutaneous
NCT02057185 · Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, and more
Local Institution - 0030
Los Angeles, California
Local Institution - 0009
Los Angeles, California
Local Institution - 0001
Atlanta, Georgia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions